A 16-week mean BMI reduction of 11.6 percent in just seven patients is a thin data set, but in a disease as poorly characterized as acquired hypothalamic obesity, that signal carries real weight. Rhythm Pharmaceuticals released preliminary Phase 2 results for RM-718, its investigational once-weekly MC4R agonist, and the number that matters most is not the efficacy figure itself but what surrounds it: the hyperpigmentation profile.
Hyperpigmentation has been the most visible liability of MC4R agonism as a drug class. In clinical studies supporting the original setmelanotide label, skin hyperpigmentation occurred in 78 percent of treated patients, a consequence of the drug’s activity at MC1R in addition to MC4R. RM-718 is engineered to be MC1R-sparing, and in this early cohort only two mild cases emerged, both confined to the injection site, with no generalized hyperpigmentation observed. That is exactly the differentiation the design was meant to produce, and it held in humans. The efficacy result, an 11.6 percent BMI reduction, aligns closely with the 10.1 percent seen with bivamelagon at 14 weeks and the 10.1 percent with setmelanotide at 16 weeks in Phase 2 and 3 trials, suggesting RM-718 is not trading tolerability for weaker effect.
The context for this program shifted substantially in March 2026, when the FDA approved an expanded indication for setmelanotide specifically covering acquired hypothalamic obesity in adults and pediatric patients aged four and older. That approval validated the MC4R pathway in this population, but it also means Rhythm is developing RM-718 against a backdrop where its own approved drug is already on the market. The strategic logic is that a cleaner tolerability profile, particularly less hyperpigmentation, expands the patient pool willing to initiate and stay on therapy. Acquired hypothalamic obesity remains a small population; epidemiological data from Germany estimated roughly 2,500 prevalent cases in 2019 and 2020, which suggests a global pool that rewards high treatment rates over broad market breadth.
The trial remains open-label, the n is seven for the primary efficacy read, and two patients discontinued due to adverse events. None of that disqualifies the signal, but it sets the precise threshold to watch: whether the MC1R-sparing effect holds as enrollment reaches the full eleven-patient cohort and extends into longer follow-up durations, because that differentiation is the entire thesis for RM-718 existing alongside setmelanotide.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
